Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 105335
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.105335
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.105335
Table 1 Summary of factors used for matching in propensity score models
Propensity score model | Factors used for matching |
Base model | Age, sex, race/ethnicity, income status, educational attainment, current smoking status, and alcohol consumption, all 18 components of the CCI, use of systemic steroids, anti-TNF inhibitors, calcineurin inhibitors, and immunomodulators |
Model 1 | Age, sex, race/ethnicity, income status, educational attainment, current smoking status, and alcohol consumption |
Model 2 | Age, sex, race/ethnicity, income status, educational attainment, current smoking status, and alcohol consumption, all 18 components of the CCI |
Model 3 | Age, sex, race/ethnicity, income status, educational attainment, current smoking status, and alcohol consumption, use of systemic steroids, anti-TNF inhibitors, calcineurin inhibitors, and immunomodulators |
Table 2 Baseline characteristics of inflammatory bowel disease cohort stratified by pneumonia status, n (%)
Characteristics | IBD cohort, n = 2810 | |
No pneumonia, n = 2678 | Pneumonia, n = 132 | |
Demographic | ||
Age in year, mean (SD) | 58.0 (17.1) | 65.4 (14.9) |
Male sex | 1017 (38) | 55 (41.7) |
Race/ethnicity | ||
Non-Hispanic White | 1937 (72.3) | 92 (69.7) |
Non-Hispanic Black | 268 (10) | > 201 |
Hispanic | 244 (9.1) | < 201 |
Non-Hispanic Asian | 39 (1.5) | < 201 |
Other | 190 (7.1) | < 201 |
Annual income | ||
< $35000 | 626 (23.4) | 52 (39.4) |
$35-75000 | 550 (20.5) | 22 (16.7) |
> $75000 | 1059 (39.5) | 27 (20.5) |
Education | ||
Highest grade: About 11 | 73 (2.7) | < 201 |
Highest grade: 12 to some college | 1019 (38.1) | 69 (52.3) |
Highest grade: College graduate | 1519 (56.7) | > 201 |
Current smoker | 231 (8.6) | < 201 |
Alcohol use | 2447 (91.4) | 118 (89.4) |
Baseline comorbid conditions | ||
Myocardial infarction | 143 (5.3) | 36 (27.3) |
Congestive heart failure | 233 (8.7) | 59 (44.7) |
Peripheral vascular disease | 441 (16.5) | 72 (54.5) |
Cerebrovascular disease | 338 (12.6) | 53 (40.2) |
Chronic pulmonary disease | 986 (36.8) | 99 (75) |
Rheumatic disease | 366 (13.7) | 32 (24.2) |
Dementia | 29 (1.1) | < 201 |
Hemiplegia or paraplegia | 57 (2.1) | < 201 |
Diabetes mellitus without complication | 288 (10.8) | 26 (19.7) |
Diabetes mellitus with complication | 265 (9.9) | 40 (30.3) |
Renal disease | 378 (14.1) | 47 (35.6) |
Mild liver disease | 633 (23.6) | 51 (38.6) |
Moderate to severe liver disease | 68 (2.5) | < 201 |
Peptic ulcer disease | 288 (10.8) | 31 (23.5) |
Any solid tumor | 391 (14.6) | 27 (20.5) |
Lymphoma or leukemia | 103 (3.8) | < 201 |
Metastatic solid tumor | 154 (5.8) | 23 (17.4) |
AIDS | 23 (0.9) | < 201 |
CCI score (SD) | 3.66 (3.55) | 4.56 (4.04) |
CCI score 0-4 | 1606 (60) | 25 (18.9) |
CCI score 5-9 | 678 (25.3) | 32 (24.2) |
CCI score ≥ 10 | 394 (14.7) | 75 (56.8) |
Baseline medications | ||
Systemic steroids | 1992 (74.4) | 121 (91.7) |
Anti-TNF inhibitor | 722 (27) | 40 (30.3) |
Calcineurin inhibitor | 261 (9.7) | 24 (18.2) |
Immunomodulators | 772 (28.8) | 40 (30.3) |
Table 3 Multivariable analyses of factors associated with pneumonia risk in the inflammatory bowel disease cohort
Category | Variable | Adjusted ORs (95%CI) |
Age at IBD diagnosis (per decade) | 0.90 (0.77-1.06) | |
Duration of IBD (per decade) | 0.97 (0.72-1.30) | |
Sex | Female | 0.83 (0.57-1.23) |
Race/Ethnicity | Non-Hispanic White | |
Non-Hispanic Black | 1.33 (0.77-2.23) | |
Hispanic | 0.38 (0.14-0.85)a | |
Non-Hispanic Asian | 1.09 (0.06-5.50) | |
Other | 0.97 (0.39-2.08) | |
Annual income | < $35000 | - |
$35-75000 | 0.61 (0.35-1.06) | |
> $75000 | 0.46 (0.26-0.81)b | |
Education | Highest grade: About 11 | - |
Highest grade: 12 to some college | 0.48 (0.21-1.22) | |
Highest grade: College graduate | 0.36 (0.15-0.97)a | |
Lifestyle choices | Current smoker | 0.93 (0.48-1.66) |
Alcohol use | 1.03 (0.56 - 2.03) | |
CCI | CCI score 0-4 | - |
CCI score 5-9 | 3.00 (1.63-5.62)b | |
CCI score ≥ 10 | 12.20 (6.69-23.00)b | |
Medication use | Systemic steroids | 2.26 (1.21-4.64)a |
Anti-TNF inhibitor | 1.39 (0.88-2.15) | |
Calcineurin inhibitor | 1.36 (0.81-2.20) | |
Immunomodulators | 0.87 (0.56-1.34) | |
Pneumococcal vaccination | 1.00 (0.65-1.52) |
- Citation: Eun Y, Culpepper-Morgan J, Akanmode AM, Thu MB, Sta Lucia AA, Thearle MS, Trousdale RK. Comorbidities and systemic steroids drive pneumonia risk in inflammatory bowel disease: Propensity score-matched cohort study. World J Gastrointest Pharmacol Ther 2025; 16(2): 105335
- URL: https://www.wjgnet.com/2150-5349/full/v16/i2/105335.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i2.105335